StreetInsider.com News Articles

Stephens Downgrades 10X Genomics (TXG) to Equal Weight

Fri, 23 Oct 2026 09:26:12 -0400

Stephens analyst Mason Carrico downgraded 10X Genomics (NASDAQ: TXG) from Overweight to Equal Weight with a price target of $65.00.

For an analyst ratings summary and ratings history on 10X Genomics click here. For more ratings news on 10X Genomics click here.

Shares of 10X Genomics closed at $69.75 yesterday.

Torex Gold adds ex-KPMG mining leader to its board of directors

Tue, 20 Oct 2026 06:01:14 -0400

Torex Gold Resources Inc. (TSX: TXG) (OTCQX: TORXF) has appointed Lee Hodgkinson to its board of directors, effective November 1, 2026, according to a company statement.

Hodgkinson brings more than 30 years of experience in public accounting and auditing in the mining industry. He served as leader of KPMG LLP's National Mining Practice in Canada for more than 20 years and as Global Mining Leader for 10 years. He currently serves on the board of Discovery Mining Ltd., where he chairs the Audit Committee.

Hodgkinson holds the Institute of Corporate Directors designation (ICD.D) from the Rotman School of Management, is a Fellow

Torex Gold Welcomes Lee Hodgkinson to Its Board of Directors

Tue, 20 Oct 2026 06:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 20, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (OTCQX: TORXF) is pleased to announce the addition of Lee Hodgkinson to its Board of Directors ("the Board") effective November 1, 2026. With the recent departure of Rodrigo Sandoval due to his appointment as Chief Financial Officer of Fresnillo plc in September, the Board will continue to be comprised of eight directors, seven of whom are independent directors.

Rick Howes, Chair of the Board, stated:

"We are very pleased to welcome Lee to the Torex Board of Directors, and look forward to benefiting from his insights, leadership,

Torex Gold Welcomes Lee Hodgkinson to Its Board of Directors

Tue, 20 Oct 2026 06:00:00 -0400

Rick Howes, Chair of the Board, stated:

"We are very pleased to welcome Lee to the Torex Board of Directors, and look forward to benefiting from his insights, leadership,

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

Tue, 13 Oct 2026 16:05:00 -0400

PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

Tue, 13 Oct 2026 16:05:00 -0400

10X Genomics (TXG) PT Raised to $70 at TD Cowen

Tue, 13 Oct 2026 09:33:00 -0400

TD Cowen analyst Dan Brennan raised the price target on 10X Genomics (NASDAQ: TXG) to $70.00 (from $47.00) while maintaining a Hold rating.

The analyst commented: "KOL Diligence Drives Model Update: Atera Increase Supports ~13% TXG Sales CAGR; KOL insight informed our model update; we raise '27-29 rev ests by ~9% (we're 7% > '29 cons). KOLs were bullish on Atera though most see cannibalization (to Visium, Xenium; more split on single cell). AI optimism is evident (biased to spatial) but is hard to quantify (Pharma is key; diligence needed). At 13x '27 EV for low-mid teens CAGR, valuation looks full.

10X Genomics (TXG) PT Raised to $70 at TD Cowen

Tue, 13 Oct 2026 09:33:00 -0400

TD Cowen analyst Dan Brennan raised the price target on 10X Genomics (NASDAQ: TXG) to $70.00 (from $47.00) while maintaining a Hold rating.

10X Genomics (TXG) PT Raised to $70 at Morgan Stanley

Tue, 13 Oct 2026 08:22:46 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on 10X Genomics (NASDAQ: TXG) to $70.00 (from $40.00) while maintaining a Equalweight rating.

10X Genomics (TXG) PT Raised to $100 at Canaccord

Mon, 12 Oct 2026 06:38:21 -0400

Canaccord analyst Kyle Mikson raised the price target on 10X Genomics (NASDAQ: TXG) to $100.00 (from $60.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A 10x Genomics, Inc. Filed by: ARK Investment Management LLC

Wed, 07 Oct 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20261007/27161920.html

10x Genomics partners with Fred Hutch on cancer research projects

Wed, 07 Oct 2026 09:01:39 -0400

10x Genomics (Nasdaq: TXG) announced a multi-project research collaboration with Fred Hutchinson Cancer Center to investigate single cell and spatial technologies in solid tumors and blood cancers, according to a company press release.

The company said the collaboration marks its first clinical research initiative to extend into blood cancers. Two projects are planned under the agreement.

The first project will use 10x Genomics' Flex Apex and Xenium platforms, with plans to expand to the Atera platform, to analyze tumor samples from bladder cancer patients treated with antibody-drug conjugates, immune checkpoint inhibitors and other therapies. The research aims to correlate drug target expression

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

Wed, 07 Oct 2026 09:00:00 -0400

Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia

PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

Wed, 07 Oct 2026 09:00:00 -0400

Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia

10X Genomics (TXG) PT Raised to $110 at Barclays

Wed, 07 Oct 2026 03:48:12 -0400

Barclays analyst Luke Sergott raised the price target on 10X Genomics (NASDAQ: TXG) to $110.00 (from $52.00) while maintaining a Overweight rating.

Torex Gold Reports Q3 2026 Production Results

Tue, 06 Oct 2026 06:00:00 -0400

Excellent quarterly performance firmly positions Torex to achieve full-year production guidance

(All amounts expressed in U.S. dollars unless otherwise stated)

Toronto, Ontario--(Newsfile Corp. - October 6, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (OTCQX: TORXF) reports preliminary third quarter 2026 gold equivalent ("AuEq") production of 131,900 ounces ("oz") and AuEq sales of 127,346 oz.¹ Year-to-date production and sales totalled 329,071 oz AuEq² and 328,918 oz AuEq², respectively, putting the Company solidly on track to achieve the midpoint of full-year production guidance of 420,000 to 470,000 oz AuEq.³

TABLE 1: PRELIMINARY THIRD QUARTER 2026 OPERATIONAL RESULTS¹

Torex Gold Reports Q3 2026 Production Results

Tue, 06 Oct 2026 06:00:00 -0400

Excellent quarterly performance firmly positions Torex to achieve full-year production guidance

(All amounts expressed in U.S. dollars unless otherwise stated)

TABLE 1: PRELIMINARY THIRD QUARTER 2026 OPERATIONAL RESULTS¹

10x Genomics begins global shipments of Atera spatial biology platform

Tue, 29 Sep 2026 09:05:45 -0400

10x Genomics (Nasdaq: TXG) announced on Sept. 29, 2026 the start of commercial shipments of its Atera spatial biology platform, which was introduced in April 2026. The Pleasanton, Calif.-based company said booked orders exceeded the 40 instruments it had expected to ship in 2026, as disclosed at its second-quarter earnings call.

Atera is designed to combine whole transcriptome analysis, sub-cellular resolution, single-cell sensitivity and large-scale profiling in a single platform. Early users at the Allen Institute generated whole transcriptome spatial datasets across more than 350,000 cells combined from human skin and duodenum tissue. The Allen Institute plans to deploy three instruments

10x Genomics launches Sentira cloud analysis platform with Nvidia

Tue, 29 Sep 2026 09:03:41 -0400

10x Genomics, Inc. (Nasdaq: TXG) announced Sentira, a cloud-based analysis platform designed to process spatial biology data, with the first offering called Sentira Spatial Analysis built using Nvidia accelerated computing technology.

According to a company press release, Sentira Spatial Analysis uses GPU acceleration to reduce spatial data processing times from hours to minutes. The platform integrates rapids-singlecell, a tool co-developed by scverse and Nvidia, which brings GPU acceleration to biological analysis methods.

Sentira Spatial Analysis is currently available at no cost through an Early Access program for researchers using either the Xenium or Atera instruments. The platform is expected to launch commercially

10x Genomics launches Sentira cloud analysis platform with Nvidia

Tue, 29 Sep 2026 09:03:41 -0400

10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

Tue, 29 Sep 2026 09:01:00 -0400

Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every researcher

PLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced

10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

Tue, 29 Sep 2026 09:01:00 -0400

Sentira Spatial Analysis leverages NVIDIA accelerated computing to cut spatial data processing times from hours to minutes, putting rapid, iterative analysis at the fingertips of every researcher

PLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced

10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands

Tue, 29 Sep 2026 09:00:00 -0400

Extraordinary early global demand, ambitious new research programs and an expansive technology roadmap mark the beginning of a new era for biological understanding

PLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the first commercial shipments of

10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands

Tue, 29 Sep 2026 09:00:00 -0400

Extraordinary early global demand, ambitious new research programs and an expansive technology roadmap mark the beginning of a new era for biological understanding

Argus Starts 10X Genomics (TXG) at Buy

Mon, 28 Sep 2026 08:00:23 -0400

(Updated - September 28, 2026 8:00 AM EDT)

Argus analyst John Eade initiates coverage on 10X Genomics (NASDAQ: TXG) with a Buy rating and a price target of $110.00.

The analyst comments "We are launching coverage of life science tools company 10x Genomics Inc. (NYSE: TXG) with a BUY rating and a target price of $110. 10x is a midcap company whose revenue is generated from the sales of instruments, consumables, and services. These consumables and solutions enable researchers to study a broad swath of biology, such as DNA and RNA expression, proteins, or epigenetics at a resolution and scale that were